Status:

COMPLETED

Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Neurotoxicity

Unspecified Adult Solid Tumor, Protocol Specific

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

RATIONALE: Vitamin E may prevent peripheral neuropathy caused by chemotherapy in patients with cancer. It is not yet known whether vitamin E is more effective than a placebo in preventing peripheral n...

Detailed Description

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to type of chemotherapy (taxane vs cisplatin vs carboplatin vs oxaliplatin vs comb...

Eligibility Criteria

Inclusion

  • Required Characteristics:
  • Scheduled to undergo curative-intent adjuvant treatment with neurotoxic chemotherapy. Patients must have had his/her tumor removed, but may have microscopic residual disease, or residual margin involvement and still be eligible.
  • The patient's chemotherapy regimen must include one or more of the following neurotoxic chemotherapeutic agents: taxanes (paclitaxel, docetaxel); platinum compounds (cisplatin, carboplatin, oxaliplatin)-(oxaliplatin patients should preferentially be enrolled in protocol N04C7 while it is available).
  • ≥ 18 years of age
  • Ability to sign informed consent and understand the nature of a placebo-controlled trial
  • ECOG Performance Status (PS) of 0, 1, or 2 e.g.
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Life expectancy ≥ 6 months
  • Contraindications:
  • Undergoing chemotherapy for palliative care
  • Pre-existing history of peripheral neuropathy due to any cause (diabetes, alcohol, toxin, hereditary, etc).
  • Prior treatment with neurotoxic chemotherapy (exception: Patient started neurotoxic chemotherapy ≤ 4 days of starting vitamin E on this study and has not been treated previously with other neurotoxic chemotherapy agents).
  • Taking regular opioid-containing medications. (Exception: opioids, given for the short term treatment of chemotherapy-induced myalgias or arthralgias caused by taxanes are permitted.)
  • Concurrent treatment with anticonvulsants, tricyclic antidepressants, or other neuropathic pain medications agents such as carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine, topical lidocaine patch, capsaicin cream, etc.
  • History of coronary artery disease (i.e. MI, PTCA, or CABG ≤ 5 years or diagnosis of congestive heart failure of any NY heart class I-IV) Valve replacements are permitted as long as patient has fully recovered from the surgery.
  • Other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient.
  • Vitamin E supplementation for any reason ≤ 7 days prior to randomization. (Exception:
  • one multivitamin per day that contains ≤ 100 IU \[mg\] of Vitamin E, will be permitted.)
  • Any of the following: pregnant women, nursing women and men or women of childbearing potential who are unwilling to employ adequate contraception
  • Taking anticoagulant medication (i.e. coumadin, low molecular weight heparin (LMWH), or platelet aggregation inhibitors such as clopidgrel or aspirin) with the exception that 1 mg/day of coumadin for central line maintenance is allowed.
  • Diagnosed diabetes requiring insulin or oral hypoglycemic medications
  • Head or neck cancers
  • Scheduled to undergo radiation therapy while on study
  • History of hemorrhagic stroke
  • Patients receiving neo-adjuvant therapy

Exclusion

    Key Trial Info

    Start Date :

    December 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2014

    Estimated Enrollment :

    207 Patients enrolled

    Trial Details

    Trial ID

    NCT00363129

    Start Date

    December 1 2006

    End Date

    August 1 2014

    Last Update

    July 6 2016

    Active Locations (69)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 18 (69 locations)

    1

    St. Joseph Medical Center

    Bloomington, Illinois, United States, 61701

    2

    Graham Hospital

    Canton, Illinois, United States, 61520

    3

    Memorial Hospital

    Carthage, Illinois, United States, 62321

    4

    Eureka Community Hospital

    Eureka, Illinois, United States, 61530